New prostate cancer drug ‘shows promise’ to treat aggressive disease, study finds

There may be a “promising new strategy” to combat aggressive strains of prostate cancer, according to a new study.

Researchers at Flinders University and the University of South Australia investigated whether to new drugsCDKI-73, has the potential to treat drug-resistant prostate cancer.

The drug is reported to “defy conventional treatments,” as stated in the study, published in the British Journal of Cancer.

MEN’S CANCER DEATHS EXPECTED TO INCREASE OVER 90% BY 2050, STUDY FINDS.

Prostate cancer is the second leading cause of cancer death in American men, after lung cancer, according to the American Cancer Society (ACS).

By 2024, 299,010 new cases will be diagnosed and more than 35,000 men will die from the disease, according to the ACS.

The disease “often develops into aggressive forms that do not respond to standard hormone therapy,” according to Flinders University.

The researchers, including professors Luke Selth and Shudong Wang, targeted cyclin-dependent kinase 9 (CDK9) – a protein responsible for the growth and survival of prostate cancer cells.

REAL INTELLIGENCE FINDS CANCER 25% ACCURATE THAN DOCTORS IN UCLA STUDY.

Selth, from Flinders University, confirmed in a press release that the CDKI-73 inhibitor has shown to be effective in inhibiting the growth of prostate cancer in models and tumor samples.

“Our research shows that CDKI-73 strongly inhibits the growth of prostate cancer, even aggressive subtypes of the disease that are resistant to current treatment,” he said.

“Importantly, CDKI-73 specifically targets cancer cells without damaging normal cells.”

In an email sent to Fox News Digital, Selth said the drug is available orally as a tablet, which could help “facilitate its use as a new treatment.”

“We still need to do more work to fully understand the potential of CDK9 inhibitors and provide new treatments for patients.”

Selth said he considers the study’s results “a major step forward in understanding the role of CDK9 in advanced prostate cancer.”

“Having said that, we still need to do a lot of work to fully understand the potential of CDK9 inhibitors and provide new treatments for patients,” he added.

CLICK HERE TO REGISTER FOR OUR LIFESTYLE

Wang, who developed CDKI-73, said in the release that the drug is “a promising candidate for the treatment of solid tumors, such as prostate cancer.”

“Our proof-of-principle study is an important step toward future clinical trials, and these findings will inform future studies on the use and effectiveness of CDKI-73 as a cancer treatment.” it’s destructive,” he continued.

CDKI-73 is currently being investigated in phase 2 clinical trials in patients with acute myeloid leukemia (AML), a type of blood cancer that affects the bone marrow and blood cells, according to Flinders University.

Although the research is “an important step forward,” Wang said, the research team plans to complete additional trials to assess the effectiveness and safety of the drug before it is given to patients.

For more articles, visit www.foxnews/health

Selth recommended all men over 50 – and those over 40 with a family history of prostate cancer – to talk to their providers about getting screened during regular check-ups.

Dr. Marc Siegel, senior medical analyst for Fox News and professor of clinical medicine at NYU Langone Medical Centerhe was not involved in the study, but he spoke about the potential of this drug.

“We know that CDK 9 is an enzyme associated with the growth of prostate cancer,” he told Fox News Digital.

“In this new study, an inhibitor of CDK 9 (CDKI-73) was found to inhibit the growth and lead to the death of prostate cancer cells in the laboratory, as well as in animals and models.”

CLICK HERE TO GET THE FOX NEWS APP

“The drug has not been used in human studies and clinical trials may be the next step,” Siegel continued. “Shows promise for treating advanced or aggressive prostate cancer.”

Fox News Digital reached out to oncologists for comment on the experimental drug.